Skip to the content
Please enable JavaScript in your browser to complete this form.
Thank you for joining the symposium. Please help complete the below questions before the meeting starts.
First Name
*
Last Name
*
Email
*
Member of
*
[Please select]
Hong Kong College of Community Medicine
The Hong Kong College of Family Physicians
The Hong Kong College of Pathologists
Hong Kong College of Physicians
Hong Kong College of Radiologists
The College of Surgeons of Hong Kong
Medical Council of Hong Kong
Not applicable
How likely do you consider dual IO therapy (nivolumab + ipilimumab) as a treatment option for your patients with cancer (of the approved indications)?
Very frequently
Moderately frequently
Rarely
Not at all
How convincing do you find the evidence for the long-term survival benefit of dual IO therapy (nivolumab + ipilimumab)?
Strongly convincing
Somewhat convincing
Neutral
Not convincing
How confident are you in managing adverse events associated with dual IO therapy (nivolumab + ipilimumab)?
Very confident
Moderately confident
Neutral
Not confident
Submit